Microbioreactor Array System Boosts Cell Culture Capacity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Microbioreactor Array System Boosts Cell Culture Capacity

ePT--the Electronic Newsletter of Pharmaceutical Technology

Microbioreactor Array System Boosts Cell Culture Capacity

BioProcessors (Woburn, MA) has developed a microbioreactor array system for high-throughput process development. The “SimCell” system applies miniaturization, microfluidics, automation, and remote monitoring and control to increase mammalian cell culture experiment capacity by as much as two orders of magnitude.

The SimCell system is configured as an array of six microbioreactors on a plate that has essentially the same footprint as a 96-well plate, with each reactor having a capacity of approximately 700 µL of liquid—a significant scale down from traditional 1-10 L capacity reactors.

The company recently completed Phase 1 of a long-term joint project with Amgen (Thousand Oaks, CA), in which it demonstrated the potential of the SimCell technology as part of a larger robot-centered system consisting of a series of unit operations, including rotating incubators, measurement stations (e.g., for pH, CO2, biomass), and filling stations.

“Ultimately, the goal of doing these processes is to apply it to a manufacturing process. The results that we have and that have been released by Amgen show that the data from the bioreactors matches perfectly with benchtop bioreactors in terms of monoclonal antibody productivity,” says Steve Tingley, vice-president of corporate development for BioProcessors. “In effect, people can scale from our system directly into their production system in the same way that they do today when they scale up from benchtop reactors to production labs.”

The system also has been designed to address the needs of manufacturers to better understand their processes, which is in line with current goals of FDA’s process analytical technologies (PAT) initiative. “The general complaint from the process development world in biotechnology manufacturing is that they don’t have enough information, they don’t know their processes well enough, and they don’t have the best processes. So typically people will do as much process development as they can in the short time they have before they have to lock the process down,” says Tingley. “With our system, we can now do thousands of experiments in that time. The payoff is a much better understood process and potentially finding a process that is going to deliver 1.5 g/L of product instead of 600 mg/L. It also could potentially identify a process where product quality would be higher.”

–Maribel Rios

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here